ESR1 and breast carcinoma: An increase in signature score following treatment would be in line with the previous reports, which have suggested that Notch signalling may be re-activated in response to endocrine therapies for ER+ breast cancer [28, 108] and to trastuzumab treatment for HER2+ breast cancer [109, 110]; for review see [6].